Treatment of children with secretory otitis media (SOM) with amoxicillin and clavulanic acid (Spektramox) or penicillin-V (Primcillin). Bacteriological findings in the nasopharynx before and after treatment.
A total of 386 children, aged 1-10, with secretory otitis media for at least 3 months were randomly allocated to 2 or 4 weeks' treatment with penicillin-V (Primcillin) or amoxicillin + clavulanic acid (Spektramox). Spektramox was superior (p < 0.01) to Primcillin in eradicating Haemophilus influenzae and Branhamella catarrhalis from the nasopharynx. No difference was noted for Streptococcus pneumoniae and haemolytic streptococci, gr. A, B, C, G. No increase in the number of beta-lactamase-producing bacteria was noted after treatment. The nasopharynx was recolonized with the same bacteria within 4 weeks from cessation of treatment.
Balle
V
V
Department of Otolaryngology, Head and Neck Surgery, Gentofte University Hospital, Copenhagen, Denmark.
Sederberg-Olsen
J
J
Thomsen
J
J
Hartzen
S
S
D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects / Q000254:growth & development; D002648:Child; D002675:Child, Preschool; D015169:Colony Count, Microbial; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009305:Nasopharynx / Q000187:drug effects / Q000382:microbiology*; D010034:Otitis Media with Effusion / Q000188:drug therapy* / Q000382:microbiology; D010404:Penicillin V / Q000627:therapeutic use*; D010406:Penicillins / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome
D010406:Penicillins; D019980:Amoxicillin-Potassium Clavulanate Combination; D010404:Penicillin V